Assenagon Asset Management S.A. Purchases 1,035,120 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Assenagon Asset Management S.A. raised its position in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 54.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,950,849 shares of the company's stock after buying an additional 1,035,120 shares during the quarter. Assenagon Asset Management S.A. owned about 2.35% of Organogenesis worth $9,443,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its holdings in Organogenesis by 15.4% in the second quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company's stock valued at $87,000 after acquiring an additional 4,130 shares during the last quarter. Mackenzie Financial Corp raised its holdings in Organogenesis by 46.1% during the second quarter. Mackenzie Financial Corp now owns 24,328 shares of the company's stock worth $68,000 after buying an additional 7,678 shares during the last quarter. Pallas Capital Advisors LLC raised its holdings in shares of Organogenesis by 70.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company's stock worth $63,000 after acquiring an additional 9,048 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Organogenesis by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company's stock valued at $755,000 after purchasing an additional 9,054 shares in the last quarter. Finally, State Street Corp lifted its stake in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company's stock valued at $4,175,000 after acquiring an additional 9,090 shares in the last quarter. 49.57% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Gary S. Gillheeney sold 55,615 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the sale, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. This represents a 1.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders sold 278,116 shares of company stock valued at $991,190. Insiders own 36.90% of the company's stock.

Organogenesis Price Performance

Organogenesis stock traded up $0.01 during mid-day trading on Friday, reaching $3.34. 550,713 shares of the company's stock were exchanged, compared to its average volume of 516,493. The business's fifty day simple moving average is $3.50 and its 200 day simple moving average is $3.09. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a one year low of $2.16 and a one year high of $4.57.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. The company had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same quarter in the previous year, the firm posted $0.02 earnings per share. On average, analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.